27-gene Immuno-Oncology (IO) Score is Associated With Efficacy of Checkpoint Immunotherapy in Advanced NSCLC: A Retrospective BC Cancer Study

Authors: Saltman, David L., Varga, Matthew G., Nielsen, Tyler J., Croteau, Nicole S., Lockyer, Heather M., Jain, Amit L., Vidal, Gregory A., Hout, David R., Schweitzer, Brock L., Seitz, Robert S., Ross, Douglas T., Gandara, David R.

Source: Clinical lung cancer. 24(2):137-144

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100183343343.0x000001&indx=1&recIds=ETOCvdc_100183343343.0x000001

A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies

Authors: Nielsen, Tyler J. ^{a, ∗}, Ring, Brian Z. ^b, Seitz, Robert S. ^a, Hout, David R. ^a, Schweitzer, Brock L. ^a

Source: In Heliyon March 2021 7(3)

The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort.

Authors: Nielsen, Tyler J.¹ (AUTHOR) TNielsen@oncocyte.com, Varga, Matthew G.¹ (AUTHOR), Cronister, Catherine T.¹ (AUTHOR), Ring, Brian Z.¹ (AUTHOR), Seitz, Robert S.¹ (AUTHOR), Ross, Douglas T.¹ (AUTHOR), Schweitzer, Brock L.¹ (AUTHOR), McGregor, Kimberly¹ (AUTHOR)

Source: Cancer Immunology, Immunotherapy. Jul2023, Vol. 72 Issue 7, p2075-2086. 12p.

Subject Terms: *TRANSITIONAL cell carcinoma, *IMMUNE checkpoint inhibitors, *SALVAGE therapy, *METASTASIS, *PROGRESSION-free survival

Company/Entity: UNITED States. Food & Drug Administration

Association with immune checkpoint inhibitor efficacy of a 27-gene classifier in renal cell cancer.

Authors: Seitz, Robert, Nielsen, Tyler J, Schweitzer, Brock Lloyd, Gandara, David R., Parikh, Mamta, Ross, Douglas Teller

Source: Journal of clinical oncology. 39(15 suppl):4575-4575

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173202748.0x000001&indx=1&recIds=ETOCvdc_100173202748.0x000001

Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients.

Authors: Seitz, Robert S., Hurwitz, Michael E., Nielsen, Tyler J., Bailey, Daniel B., Varga, Matthew G., Ring, Brian Z., Metts, Carrie F., Schweitzer, Brock L., McGregor, Kimberly, Ross, Douglas T.

Source: Journal of Translational Medicine; 8/16/2022, Vol. 20 Issue 1, p1-11, 11p

Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer.

Authors: Ranganath, Harsha, Jain, Amit L., Smith, Justin R., Ryder, Julie, Chaudry, Amina, Miller, Emily, Hare, Felicia, Valasareddy, Poojitha, Seitz, Robert S., Hout, David R., Varga, Matthew G., Schweitzer, Brock L., Nielsen, Tyler J., Mullins, Janice, Ross, Douglas T., Gandara, David R., Vidal, Gregory A.

Source: BMC Cancer; 4/14/2022, Vol. 22 Issue 1, p1-10, 10p

Subject Terms: IMMUNE checkpoint inhibitors, NON-small-cell lung carcinoma, PROGRESSION-free survival, PROGNOSIS, TUMOR markers, PEMETREXED, PEMBROLIZUMAB

Characterization of the tumor immune-microenvironment of adenocarcinoma of lung with a metastatic lesion in the pancreas treated successfully with first-line, single-agent pembrolizumab.

Authors: Saltman, David L., Nielsen, Tyler J., Salina, Davide, Hout, David R., McMahon, Frank B., Valev, Boris R., Huk, Michael, Chandra, Pranil K., Spille, Jeremy, Seitz, Robert S., Schweitzer, Brock L.

Source: Therapeutic Advances in Medical Oncology; 4/19/2021, p1-7, 7p

Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research.

Authors: Espinosa Fernandez, Jose Rodrigo, Eckhardt, Bedrich L., Lee, Jangsoon, Lim, Bora, Pearson, Troy, Seitz, Rob S., Hout, David R., Schweitzer, Brock L., Nielsen, Tyler J., Lawrence, O. Rayne, Wang, Ying, Rao, Arvind, Ueno, Naoto T.

Source: PLoS ONE; 4/30/2020, Vol. 15 Issue 4, p1-8, 8p

Subject Terms: TRIPLE-negative breast cancer, CELL lines, TRANSLATIONAL research, CANCER cells, GENE expression profiling

This result is not displayed to guests.
Login for full access.

A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer.

Authors: Iwase, Toshiaki, Blenman, Kim R. M., Li, Xiaotong, Reisenbichler, Emily, Seitz, Robert, Hout, David, Nielsen, Tyler J., Schweitzer, Brock L., Bailey, Daniel B., Shen, Yichao, Zhang, Xiang, Pusztai, Lajos, Ueno, Naoto T.

Source: Cancers; Oct2021, Vol. 13 Issue 19, p4839, 1p

Subject Terms: BREAST cancer prognosis, PILOT projects, PREDICTIVE tests, SEQUENCE analysis, CELL physiology, IMMUNOLOGICAL adjuvants, GENE expression profiling, DESCRIPTIVE statistics, COMBINED modality therapy, TUMOR markers, POLYMERASE chain reaction, ODDS ratio, MEMBRANE proteins, PREDICTION models, CHEMICAL inhibitors